FDA emergency use submission delayed to Q4
FDA emergency use submission delayed to Q4
Novavax announced that it will delay the submission of its Covid-19 vaccine to the Food and Drug Administration for emergency use authorization until its fourth quarter.
Shares of the biotechnology company slipped 10% after the bell.
The company has filed for regulatory approval in India, Indonesia and the Philippines. Plans to submit the vaccine for emergency use listing at the World Health…